Board of Directors

Heather Mason Chair of the Board, Former Senior Executive of Abbott Laboratories
More

Ms. Mason has served as a director of Assertio since February 2019. Ms. Mason is a former senior executive of Abbott Laboratories, having recently retired as executive vice president (EVP) of Abbott Nutrition. Ms. Mason also served as EVP, global commercial Operations at Abbott and senior vice president of Abbott Diabetes Care. Ms. Mason joined Abbott in 1990 and held positions in Abbott’s U.S. pharmaceutical business, including oversight of Abbott’s specialty pharmaceuticals, its diabetes/metabolics and oncology franchises, and managed health care. Ms. Mason also served as vice president (VP), international marketing, and VP, Latin American operations, in Abbott’s international pharmaceutical business. Prior to joining Abbott, Ms. Mason worked for Quaker Oats, FMC Corporation, and Commonwealth Edison. Ms. Mason holds a B.S.E. in Industrial Engineering from the University of Michigan and a M.B.A. from the University of Chicago.

Sigurd C. Kirk Former Executive Vice President, Allergan plc.
More

Mr. Kirk has served as a director of Assertio since April 2024. Mr. Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products. Since 2021, Mr. Kirk has served as a consultant and director to privately-held pharmaceutical companies and, from May 2021 to January 2024, served as a director and member of the audit committee of Aravive, Inc., a development stage oncology company. From 2009 until its acquisition by AbbVie Inc. in May 2020, Mr. Kirk held various positions at Allergan plc. (formerly Actavis), a pharmaceutical company. From May 2012 until May 2020, Mr. Kirk was Executive Vice President, Corporate Business Development at Allergan plc., where he was a member of the Executive Leadership Team. He was an integral member assessing development and commercial opportunities, leading due diligence, as well as negotiating and transacting key legal and financial terms. Mr. Kirk also served as Senior Vice President, Global Controller and Chief Accounting Officer for Barr Pharmaceuticals, Inc. from 2007 until 2009, after having served in positions of increasing responsibility at Barr from 2003. Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification. Mr. Kirk received his Bachelor of Business Administration degree from Pace University.

Brendan P O’Grady Chief Executive Officer of Assertio Holdings
More

Mr. O’Grady, age 57, most recently served as CEO of the Global Formulations Business at Glenmark Pharmaceuticals Ltd. (India: NSE), a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O’Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell (NYSE: AMWL), an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), from 2001 to 2021, most recently serving as CEO and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva’s North America business, including specially, generic and over-the-counter pharmaceuticals, and the abbreviated new drug application drug distribution business. Prior to that, Mr. O’Grady served in various positions of increasing responsibility at Sanofi (Nasdaq: SNY) from 1991 to 2001. Mr. O’Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York and an M.B.A. from Baker University

Mark Reisenauer
More

Mr. Reisenauer is an accomplished oncology and hematology biopharmaceutical executive with more than 30 years of experience building commercial capabilities and leading successful new product and indication launches. He previously served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., where he grew sales to nearly $5 billion while leading Marketing, Sales, Policy and Government Affairs and Market Access teams. Prior to Astellas, he was Senior Vice President and Chief Commercial Officer at Micromet, Inc., which was acquired by Amgen, where he oversaw commercial launch and pipeline development activities. He was also at Abbott Laboratories, serving as a divisional vice president for neuroscience and general manager in oncology products. Earlier in his career, Mr. Reisenauer held roles at Pharmacia Corporation, Bristol-Myers Squibb and Zeneca Pharmaceuticals. He holds a Bachelor of Arts degree in political science from the University of Wisconsin.

Sravan Emany Chief Financial Officer, Ironwood Pharmaceuticals
More

Mr. Emany has served as a director of Assertio since November 2023. Since December 2021, Mr. Emany has served as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, a Nasdaq listed healthcare company. Prior to joining Ironwood, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation, a publicly traded global healthcare company, from March 2020 until December 2021 and as Vice President of Strategy, Treasury and Investor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.

William T. McKee Former Chief Financial Officer, Barr Pharmaceuticals
More

Mr. McKee has served as director of Assertio since March 2017. He served as chief operating officer and chief financial officer (CFO) at EKR Therapeutics, Inc., a privately held specialty pharmaceutical company from 2010 until EKR was sold to Cornerstone Therapeutics Inc. in 2012. Until March 2010, Mr. McKee served as the executive vice president and CFO of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited, a generic pharmaceutical company, and the successor entity to Barr Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company, which was acquired by Teva. Mr. McKee was also executive vice president and CFO of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr until its acquisition. Prior to joining Barr, Mr. McKee served as director of International Operations and vice president of finance at Absolute Entertainment, Inc., a private developer and marketer of entertainment software. Mr. McKee previously worked at Gramkow & Carnevale, CPAs and Deloitte & Touche. Mr. McKee serves on the boards of Agile Therapeutics, Inc., a publicly held specialty biopharmaceutical company, Cerulean, Inc., a publicly held clinical-stage, oncology-focused company and Synthetic Genomics Inc., a privately held synthetic biology company. Mr. McKee received a B.A. in business from the University of Notre Dame.

David Stark Former Chief Legal Officer, Teva Pharmaceuticals
More

Mr. Stark has served as a director of Assertio since November 2024. Mr. Stark served as Chief Legal Officer of Teva Pharmaceutical Industries Ltd. (“Teva Pharmaceuticals”) from 2016 to 2024. Mr. Stark joined Teva Pharmaceuticals in 2002 and served in a series of roles with increasing responsibilities in Teva North America and Teva Americas, including as Senior Director, Deputy General Counsel, Vice President and General Counsel, and Senior Vice President and General Counsel, Global Specialty Medicines. Prior to joining Teva, Mr. Stark was an associate attorney in the litigation departments at Willkie Farr & Gallagher LLP between 1998 and 2002, Chadbourne & Parke between 1997 and 1998 and Haight, Gardner, Poor & Havens between 1994 and 1997. Mr. Stark is Founder and CEO of Stark Creative Solutions LLC, specializing in innovative solutions to legal challenges. Mr. Stark holds a J.D. from New York University School of Law and a B.A. in Political Science from Northeastern University, summa cum laude.